Cargando…
LECT 2 Antagonizes FOXM1 Signaling via Inhibiting MET to Retard PDAC Progression
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers with minimally effective treatments, highlighting the importance of developing novel biomarkers and therapeutic targets. Here, we disclosed the mechanisms that leukocyte cell-derived chemotaxin-2 (LECT2) modulates PDAC develop...
Autores principales: | Li, Xin, Lin, Pingping, Tao, Ye, Jiang, Xin, Li, Ting, Wang, Yunshan, Wang, Chenjing, Cao, Yu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082113/ https://www.ncbi.nlm.nih.gov/pubmed/33937262 http://dx.doi.org/10.3389/fcell.2021.661122 |
Ejemplares similares
-
Cell Lineage Infidelity in PDAC Progression and Therapy Resistance
por: Malinova, Antonia, et al.
Publicado: (2021) -
Identification of DDX31 as a Potential Oncogene of Invasive Metastasis and Proliferation in PDAC
por: Xie, Yongjie, et al.
Publicado: (2022) -
Opposite Roles of Tumor Cell Proliferation and Immune Cell Infiltration in Postoperative Liver Metastasis of PDAC
por: Wang, Guangfu, et al.
Publicado: (2021) -
Modulation of Type I Interferon Responses to Influence Tumor-Immune Cross Talk in PDAC
por: Cattolico, Carlotta, et al.
Publicado: (2022) -
PDAC as an Immune Evasive Disease: Can 3D Model Systems Aid to Tackle This Clinical Problem?
por: Narayanan, Shruthi, et al.
Publicado: (2021)